Adults 18 to 45, any sex, with Malaria, Vivax. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Efficacy of the ChAd63 and MVA PvDBP Vaccines, Administered in a Heterologous Prime-boost Regimen, Assessed by a Reduced Parasite Multiplication Rate in Vaccinated SubjectsPrimary· 3 months post CHMI
Quantitative PCR-derived parasite multiplication rate (PMR) will be the primary efficacy endpoint and a comparison of the endpoint between Groups 1, 2 and 3 (pooled data) and malaria-naïve controls partaking in simultaneous CHMI, under identical conditions, will constitute the primary analysis for efficacy.
Group
Value
95% CI
Groups 1, 2 and 3 Volunteers Completing CHMI
5.4
4.0 – 7.3
Safety of the ChAd63 and MVA PvDBP Vaccines Andidates, Administered in a Heterologous Prime-boost Regimen in a CHMI Study in Healthy VolunteersSecondary· Within 28 days following each vaccination. Vaccinations occurred at 0 and 2 months in Groups 1 and 3 (ChAd63, MVA PvDBP); and at 0, 17 and 19 months in Group 2 (ChAd63, ChAd63, MVA PvDBP).
No of participants reporting adverse event
Any grade 3 solicited adverse event
Group
Value
95% CI
Following ChAd63 PvDBP Vaccination
1
Following MVA PvDBP Vaccination
2
Any grade 3 unsolicited adverse event
Group
Value
95% CI
Following ChAd63 PvDBP Vaccination
0
Following MVA PvDBP Vaccination
0
Any grade 3 laboratory adverse event
Group
Value
95% CI
Following ChAd63 PvDBP Vaccination
1
Following MVA PvDBP Vaccination
0
The Humoral Immunogenicity ChAd63 and MVA PvDBP Vaccine Candidates, Administered in a Heterologous Prime-boost RegimenSecondary· 14 days after the final vaccination. Final vaccinations (MVA PvDBP) occurred at 2 months in Groups 1 and 3; and at 19 months in Group 2.
Total IgG antibody response to the P. vivax Duffy-binding protein (PvDBP)
Group
Value
95% CI
Groups 1, 2 and 3 Volunteers
29
9 – 85
The Cellular Immunogenicity ChAd63 and MVA PvDBP Vaccine Candidates, Administered in a Heterologous Prime-boost RegimenSecondary· 14 days after the final vaccination. Final vaccinations (MVA PvDBP) occurred at 2 months in Groups 1 and 3 ; and at 19 months in Group 2.
PvDBPII-specific CD4+ CD45RA- CCR7- effector memory T cells producing IFN-γ
Group
Value
95% CI
Groups 1, 2 and 3 Volunteers
0.6825
0.09500 – 1.951
Adverse events — posted to ClinicalTrials.gov
Time frame: Data on solicited adverse events were collected for 7 days after vaccination and unsolicited adverse events for 28 days post-vaccination. Serious adverse events were collected for the study duration: up to 12 months for Group 1 and 3 participants, and up to 29 months for Group 2 participants..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection.
The participants will receive one or two doses of ChAd63 PvDBP followed by one dose of MVA PvDBP 8 weeks later.
Approximately 4 weeks after the second vacccination, the volunteers will be challenged (deliberately infected) with malaria by intravenous injection blood-stage
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken
· Phase 3
· recruiting
NCT05788094 — ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
· Phase 4
· recruiting
Other University of Oxford trials
Trials by the same sponsor.
NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
· Phase 2
· not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
· Phase 1
· not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis
· not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE
· Phase 3
· not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04009096.